Clinical Trials Directory

Trials / Completed

CompletedNCT00276016

The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)

Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Organon and Co · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

This is a Phase 3, single-dose, investigator-blind, randomized, placebo-controlled, crossover study, conducted at a single site in Austria, outside of the normal grass pollen season. An allergic reaction will be induced by exposing subjects to grass pollen in the Vienna Challenge Chamber (VCC). Subjects will receive a single dose of each of the following treatments according to a randomization sequence: Phenylephrine 12 mg immediate-release capsule, pseudoephedrine 60 mg immediate-release tablet, and placebo capsule. There will be a minimum of a 5-day washout period between each treatment. Subjects will complete symptom evaluations throughout the study. The nasal decongestant effects of phenylephrine will be compared to those of placebo using the subjective symptom evaluations. The safety profile (adverse events and vital signs) of the treatments will also be evaluated.

Conditions

Interventions

TypeNameDescription
DRUGphenylephrineimmediate-release 12 mg capsules for oral administration
DRUGpseudoephedrine60 mg immediate-release tablets for oral administration
DRUGplaceboplacebo capsules

Timeline

Start date
2006-01-01
Primary completion
2006-02-01
Completion
2006-02-01
First posted
2006-01-12
Last updated
2022-02-09
Results posted
2010-07-29

Source: ClinicalTrials.gov record NCT00276016. Inclusion in this directory is not an endorsement.